Reversal of retinal ganglion cell dysfunction happens after IOP reduction

Article

A study has shown that the surgical reduction of IOP causes the reversal of retinal ganglion cell (RGC) dysfunction.

A study has shown that the surgical reduction of IOP causes the reversal of retinal ganglion cell (RGC) dysfunction. It was also found that the pattern electroretinogram optimized for glaucoma screening (PERGLA) can be a non-invasive technique to measure RGC function.

Mitra Sehi, Research Assistant Professor of Ophthalmology at Bascom Palmer Eye Institute, University of Miami, USA, conducted a prospective cohort study of 47 eyes of 47 patients with uncontrolled IOP. The patients underwent a total ocular examination, arterial blood pressure, standard automated perimetry (SAP) and PERGLA before surgery and three months after surgery.

The results indicated that mean postoperative IOP was significantly reduced compared with preoperative IOP. PERGLA amplitude after surgery increased compared to preoperative PERGLA amplitude. Thirty-four of the 47 eyes underwent trabeculectomy with antifibrosis therapy, 13 eyes had glaucoma drainage implant surgery.

The conclusion was that the reversal of RGC dysfunction happens after surgical reduction of IOP and can be measured using PERGLA.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.